Close Menu

NEW YORK (GenomeWeb) – A multi-basket trial launched by the American Society of Clinical Oncology three years ago has reported out the first positive data from two arms demonstrating activity for Pfizer's palbociclib (Ibrance) and Merck's pembrolizumab (Keytruda) in biomarker-defined cancers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.